#1 Clinical Trials Search in Europe

Interferon Beta-1B

Interferon Beta-1B has been the subject of several clinical trials, investigating its efficacy in treating multiple sclerosis (MS) and more recently, COVID-19. These studies aim to evaluate the drug’s potential benefits, safety profile, and its role in combination therapies for these conditions. The trials span various aspects of treatment, from long-term effects in MS to potential antiviral properties in COVID-19 patients.

Table of Contents

What is Interferon Beta-1b?

Interferon Beta-1b is a medication primarily used in the treatment of multiple sclerosis (MS). It is known by several brand names, including Betaferon[1], Betaseron[2], and BAY86-5046[1]. This drug belongs to a class of medications called interferons, which are proteins naturally produced by the body to help fight infections and regulate the immune system.

Conditions Treated by Interferon Beta-1b

Interferon Beta-1b is primarily used to treat various forms of multiple sclerosis, including:

  • Relapsing-remitting multiple sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of remission[3].
  • Secondary progressive multiple sclerosis (SPMS): A stage of MS that can follow RRMS, where disability steadily worsens[4].
  • Clinically isolated syndrome (CIS): A first episode of neurologic symptoms that might be the beginning of MS[4].

Interestingly, recent research has also explored the potential use of Interferon Beta-1b in treating COVID-19[5].

How Interferon Beta-1b Works

Interferon Beta-1b works by modulating the immune system. In multiple sclerosis, the body’s immune system mistakenly attacks the protective covering of nerve fibers (myelin) in the brain and spinal cord. Interferon Beta-1b helps to:

  • Reduce inflammation in the central nervous system
  • Decrease the number of harmful immune cells that can damage myelin
  • Potentially slow down the progression of disability in MS

While the exact mechanism is not fully understood, these actions help to reduce the frequency and severity of MS relapses and slow the accumulation of physical disability[3].

How Interferon Beta-1b is Administered

Interferon Beta-1b is typically administered as a subcutaneous (under the skin) injection. The standard dose is usually 250 micrograms (μg) or 8 million International Units (MIU) every other day[1]. Patients or their caregivers can be trained to administer the injections at home. Some key points about administration include:

  • The injection site should be rotated to minimize skin reactions
  • The medication is usually stored in a refrigerator but should be allowed to warm to room temperature before injection
  • Some studies have explored higher doses (500 μg) or different administration schedules, but these are not standard practice[6]

Efficacy of Interferon Beta-1b

Several clinical trials have demonstrated the efficacy of Interferon Beta-1b in treating multiple sclerosis. Key findings include:

  • Reduction in relapse rates: Patients treated with Interferon Beta-1b experience fewer MS relapses compared to those not on treatment[3].
  • Slowing of disease progression: The medication may help slow the accumulation of disability over time[2].
  • MRI improvements: Interferon Beta-1b has been shown to reduce the number of new brain lesions visible on MRI scans[2].
  • Early treatment benefits: Starting treatment early in the course of MS (even after the first clinical event suggestive of MS) may lead to better long-term outcomes[2].

Potential Side Effects

Like all medications, Interferon Beta-1b can cause side effects. Common side effects include:

  • Flu-like symptoms: Including fever, chills, and muscle aches, especially after the first few injections[6].
  • Injection site reactions: Redness, pain, or swelling at the injection site[6].
  • Liver enzyme elevations: Regular blood tests may be required to monitor liver function[6].
  • Hematological abnormalities: Changes in blood cell counts may occur[6].

Most side effects are manageable and tend to decrease over time. Patients should always discuss any concerns about side effects with their healthcare provider.

Ongoing Research and New Applications

Research into Interferon Beta-1b continues, with several interesting developments:

  • COVID-19 treatment: Some studies are exploring the potential use of Interferon Beta-1b in combination with other drugs to treat COVID-19[5][7]. Early results suggest it may help reduce viral load and improve recovery time in COVID-19 patients.
  • Improved delivery methods: Researchers are investigating ways to improve the administration of Interferon Beta-1b, including the use of electronic reminders to enhance treatment adherence[1].
  • Combination therapies: Studies are exploring the potential benefits of combining Interferon Beta-1b with other MS treatments or using it in specific patient subgroups[8].

These ongoing research efforts aim to optimize the use of Interferon Beta-1b and potentially expand its applications beyond multiple sclerosis treatment.

Aspect Details
Primary Conditions Studied Multiple Sclerosis (MS), COVID-19
Administration Method Subcutaneous injection, typically every other day
Dosage Range 250 μg to 500 μg (8-16 million IU)
Common Combination Therapies Hydroxychloroquine, Lopinavir/Ritonavir, Ribavirin, Clofazimine
Key Outcome Measures Time to clinical improvement, relapse rates, MRI lesion activity, disability progression
Safety Considerations Injection site reactions, flu-like symptoms, liver function changes
Trial Durations Range from several months (COVID-19) to several years (MS studies)

FAQ

  • What is Interferon Beta-1B? Interferon Beta-1B is a medication commonly used in the treatment of multiple sclerosis. It's a type of protein that helps regulate the immune system and has shown potential antiviral properties.
  • How is Interferon Beta-1B administered? Interferon Beta-1B is typically administered through subcutaneous injections, usually every other day. The dosage can vary depending on the specific treatment protocol.
  • What conditions are being studied with Interferon Beta-1B? Clinical trials are exploring the use of Interferon Beta-1B primarily in multiple sclerosis treatment. More recently, it has also been studied as a potential treatment for COVID-19.
  • Are there any side effects associated with Interferon Beta-1B? Like all medications, Interferon Beta-1B can have side effects. Common ones include injection site reactions, flu-like symptoms, and in some cases, changes in liver function. The clinical trials aim to further assess its safety profile.
  • How long do the clinical trials for Interferon Beta-1B typically last? The duration of clinical trials varies. Some studies, particularly those for multiple sclerosis, can last several years to assess long-term effects. COVID-19 related trials tend to be shorter, often lasting a few months.

Ongoing Clinical Trials on Interferon Beta-1B

  • Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerves.
  • Relapsing-Remitting Multiple Sclerosis (RR-MS): A form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • SARS-CoV-2: The virus responsible for causing COVID-19 (Coronavirus Disease 2019).
  • Subcutaneous injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis, ranging from 0 (normal neurological exam) to 10 (death due to MS).
  • Magnetic Resonance Imaging (MRI): A medical imaging technique used to form pictures of the anatomy and physiological processes of the body, often used in MS to detect lesions.
  • T2-weighted images: A type of MRI image where fluids appear bright, used to detect MS lesions.
  • Gadolinium (Gd)-enhancing lesions: Active MS lesions that show up on MRI scans after the injection of a contrast agent called gadolinium.
  • Annualized relapse rate: The average number of relapses a patient experiences in a year, used to measure disease activity in MS.
  • Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection that can occur in some MS patients on certain treatments.

References

  1. https://clinicaltrials.gov/study/NCT00902135
  2. https://clinicaltrials.gov/study/NCT00185211
  3. https://clinicaltrials.gov/study/NCT01701856
  4. https://clinicaltrials.gov/study/NCT03408093
  5. https://clinicaltrials.gov/study/NCT04465695
  6. https://clinicaltrials.gov/study/NCT00459667
  7. https://clinicaltrials.gov/study/NCT04647695
  8. https://clinicaltrials.gov/study/NCT01111656